Enhancement of Microglia Functions by Developed Nano‐Immuno‐Synergist to Ameliorate Immunodeficiency for Malignant Glioma Treatment
Authors:
- 12 September 2023
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (30) , e2301861
Abstract
Resident microglia are key factors in mediating immunity against brain tumors, but the microglia in malignant glioma are functionally impaired. Little immunotherapy is explored to restore microglial function against glioma. Herein, oleanolic acid (OA) (microglia “restorer”) and DPPA‐1 peptide (immune checkpoint blockade) are integrated on a nano‐immuno‐synergist (DPAM@OA) to work coordinately. The self‐assembled OA core is coated with macrophage membrane for efficient blood–brain barrier penetration and microglia targeting, on which DPPA‐1 peptide is attached via acid‐sensitive bonds for specific release in tumor microenvironment. With the enhanced accumulation of the dual drugs in their respective action sites, DPAM@OA effectively promotes the recruitment and activation of effector T cells by inhibiting aberrant activation of Signal transducer and activator of transcription (STAT‐3) pathway in microglia, and assists activated effector T cells in killing tumor cells by blocking elevated immune checkpoint proteins in malignant glioma. Eventually, as adjuvant therapy, the rationally designed nano‐immuno‐synergist hinders malignant glioma progression and recurrence with or without temozolomide. The work demonstrates the feasibility of a nano‐formulation for microglia‐based immunotherapy, which may provide a new direction for the treatment of brain tumors.Keywords
Funding Information
- National Natural Science Foundation of China (82073780, 82273868, 81690263)
- Natural Science Foundation of Shanghai Municipality (19ZR1406200)
This publication has 103 references indexed in Scilit:
- Interleukins in glioblastoma pathophysiology: implications for therapyBritish Journal of Pharmacology, 2013
- Impact of Temozolomide on Immune Response during Malignant Glioma ChemotherapyJournal of Immunology Research, 2012
- Differential macrophage programming in the tumor microenvironmentTrends in Immunology, 2012
- Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platformProceedings of the National Academy of Sciences, 2011
- The Cell-Specific Induction of CXC Chemokine Ligand 9 Mediated by IFN-γ in Microglia of the Central Nervous System Is Determined by the Myeloid Transcription Factor PU.1The Journal of Immunology, 2010
- Experience with irinotecan for the treatment of malignant gliomaNeuro-Oncology, 2009
- CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitisProceedings of the National Academy of Sciences, 2008
- Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6—STAT3 signaling pathwayProceedings of the National Academy of Sciences, 2008
- A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma PatientsCancer Research, 2007
- IL-6 is required for glioma development in a mouse modelOncogene, 2004